June 20, 2026 · 13 min read
The world's first CRISPR therapy — Casgevy — was approved in December 2023 and has since treated ~60 patients globally. Intellia Therapeutics demonstrated 97% reduction in disease-causing protein with a single in vivo CRISPR injection. Beam Therapeutics reported positive Phase 1/2 base editing data in 2026. Meanwhile, longevity capital hit ~$5B invested in 2025 (Altos Labs alone raised $3B). This is a two-track sector: near-term CRISPR revenue plays and longer-term longevity biology bets. Here is the complete framework.
This sector contains two distinct investment tracks with different timelines, risk profiles, and catalysts. Understanding the split is essential before allocating capital.
CRISPR companies are editing DNA to cure specific genetic diseases — sickle cell, transthyretin amyloidosis, hereditary angioedema. Casgevy is already approved and generating commercial revenue. Intellia has Phase 3 programs. These are clinical-stage biotechs with binary trial outcomes and identifiable FDA approval timelines. Speculative, but with a clear near-term value-realization path.
Longevity biology targets the fundamental mechanisms of aging itself — senescent cell clearance, epigenetic reprogramming, mTOR pathway modulation. Most leading companies (Altos Labs, Calico) are private and pre-clinical. Public pure-plays are few and small. This is closer to early-stage venture investing: enormous upside if the science works, extreme uncertainty on timelines.
CRISPR-Cas9 was adapted from a bacterial immune system. The Cas9 protein acts as molecular scissors, guided to an exact DNA sequence by a synthetic "guide RNA." Once there, it cuts both strands of the DNA double helix. The cell's repair machinery then either disables the gene (knockdown) or, if a repair template is provided, inserts a corrected sequence (correction). The technology earned a Nobel Prize in 2020 and went from academic discovery to approved human therapy in just 11 years — historically fast for medicine.
On December 8, 2023, the FDA approved Casgevy (exagamglogene autotemcel, or exa-cel) — making it the first CRISPR-based medicine cleared for human use anywhere in the world. Co-developed by CRISPR Therapeutics and Vertex Pharmaceuticals, Casgevy is approved for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).
Sickle cell disease is caused by a single mutation in the HBB gene that produces abnormal hemoglobin, causing red blood cells to deform into a crescent shape that blocks blood vessels and causes excruciating pain crises. Casgevy takes a different approach than correcting the HBB gene directly: it reactivates a fetal hemoglobin gene (HBF) that the body naturally turns off after birth. Fetal hemoglobin is functionally normal and can compensate for the defective adult hemoglobin. CRISPR edits the BCL11A gene — which acts as an off switch for fetal hemoglobin — restoring production to therapeutic levels.
The gap between ~60 patients treated and ~100,000 eligible is not just a demand problem — it is a manufacturing and logistics challenge. The ex vivo process requires collecting a patient's stem cells, shipping them to a manufacturing facility, editing them, quality-controlling the product, and infusing them back after a harsh conditioning regimen. Each patient takes 6–9 months. Vertex has built out a global network of authorized treatment centers, but ramping throughput is slow. The $2.2M price tag also creates payer access hurdles, though outcomes-based contracts are being negotiated with insurers who recognize that curing SCD is cheaper than lifetime hydroxyurea therapy plus hospitalizations. This is a long commercial ramp story — think 5–10 years to reach meaningful patient volumes.
The four major public CRISPR companies each take a meaningfully different technological approach with different risk profiles, cash runways, and timelines to value creation.
| Ticker | Platform | Lead Program | Cash | Runway | Mkt Cap |
|---|---|---|---|---|---|
| NTLA | In vivo CRISPR | NTLA-2001 (ATTR amyloidosis) — Phase 3 | ~$900M | 3–4 years | ~$2.5B |
| CRSP | Ex vivo CRISPR + CAR-T | Casgevy — APPROVED for SCD & beta-thal | ~$1.8B | 5+ years | ~$3.1B |
| BEAM | Base editing | BEAM-302 (A1AD) — Phase 1/2 positive data | ~$1.1B | 4–5 years | ~$1.8B |
| EDIT | CRISPR-Cas9 + Cas12a | EDIT-301 (SCD) — Phase 1/2 | ~$350M | ~2 years | ~$500M |
Intellia is the most important pure-play CRISPR company for investors focused on technology paradigm shifts. Its entire platform is built around in vivo CRISPR delivery — editing DNA inside the body without removing cells. If in vivo delivery works at scale, it removes the manufacturing complexity that constrains Casgevy's commercial ramp and opens CRISPR to diseases that cannot be addressed by ex vivo editing.
ATTR amyloidosis is caused by misfolded transthyretin (TTR) protein produced in the liver that accumulates in the heart and nerves. Intellia's NTLA-2001 — co-developed with Regeneron — uses LNP-delivered CRISPR to knock out the TTR gene in liver cells, stopping production of the harmful protein at the source. A single injection in Phase 1 trials produced a 97% median reduction in serum TTR levels, sustained for 12+ months. Phase 3 enrollment is complete and data is expected in 2026–2027. The commercial market (validated by Alnylam's Onpattro/Vutrisiran RNA therapies, which do the same thing less permanently) is multi-billion dollars annually.
HAE is a rare genetic disease causing sudden swelling attacks in skin, gut, and airways — sometimes fatal. Intellia's wholly owned NTLA-2002 targets the KLKB1 gene in the liver, reducing plasma kallikrein. Phase 3 data is a key 2026 catalyst — wholly owned means Intellia captures 100% of economics if approved. HAE is a validated commercial market (KalVista, Beigene, and BioCryst all have approved therapies), so pricing and reimbursement frameworks exist.
The bear case for Intellia: in vivo editing has only been demonstrated durable in the liver. The liver preferentially takes up LNPs. Expanding in vivo CRISPR to muscle, lung, brain, or eye requires different delivery vehicles — viral vectors, engineered LNPs, or other approaches — that are harder and earlier-stage. Intellia's current pipeline is therefore largely a liver disease company, limiting addressable market in the near term.
Beam Therapeutics was founded by David Liu, Feng Zhang, and J. Keith Joung — three of the most cited scientists in the gene editing field. The company's platform is based on David Liu's base editing technology developed at the Broad Institute: rather than cutting DNA with a molecular scissors, base editors use a chemically modified Cas9 that has lost its cutting ability, fused to a DNA-modifying enzyme. The result is a "molecular pencil" that converts C to T (CBEs) or A to G (ABEs) without making double-strand breaks.
Double-strand DNA breaks — what CRISPR-Cas9 creates — trigger cellular repair mechanisms that can introduce unintended insertions or deletions at off-target sites. Base editing bypasses this by avoiding the break entirely. For diseases caused by single-letter mutations (the majority of Mendelian genetic diseases), base editing is potentially more precise and safer. First in-human base editing data from BEAM-302 in 2026 is a landmark moment — if results are clean, it validates the entire next-generation approach.
Beam's risk is timing and execution. Base editing is a generation behind standard CRISPR commercially — Casgevy is approved while Beam's lead programs are Phase 1/2. The question is whether the precision advantage translates into superior clinical results that justify later arrival. If BEAM-302 data shows both efficacy and a clean safety profile, the stock re-rates on platform validation. If early signals disappoint, the market will question whether the additional precision is needed clinically or just academically interesting.
Ex vivo CRISPR editing (Casgevy's approach) works — but it requires removing cells from the patient, editing them in a lab, and reinfusing them. This limits it to diseases involving accessible cells: blood stem cells for sickle cell disease, T-cells for cancer immunotherapy. The vast majority of genetic diseases — liver diseases, neurological disorders, muscle diseases, cardiac conditions — cannot be addressed by removing and editing cells.
In vivo CRISPR delivery — injecting CRISPR components directly into the body — is the approach that would make gene editing broadly accessible. The key challenge: getting CRISPR components into the right cells inside the body without triggering immune reactions, causing off-target edits, or accumulating in the wrong tissues.
In 2013, Carlos Lopez-Otin and colleagues published "The Hallmarks of Aging" in Cell — one of the most cited papers in biology. In 2023, the framework was updated to 12 hallmarks, adding three new ones (disabled macroautophagy, chronic inflammation, dysbiosis). These hallmarks define the target landscape for longevity biotechnology.
Senescent cells are cells that have stopped dividing but haven't died. They secrete a cocktail of inflammatory signals called the Senescence-Associated Secretory Phenotype (SASP) that damages surrounding tissue, drives chronic inflammation, and is strongly linked to age-related diseases including diabetes, cardiovascular disease, and neurodegeneration. Senolytics are drugs that selectively kill senescent cells — and animal studies show remarkable results: cleared mice live 25–35% longer and remain healthier.
David Sinclair (Harvard) and others have demonstrated that biological aging is at least partially driven by epigenetic changes — modifications to how DNA is packaged and read, not the DNA sequence itself. Yamanaka factors (Oct4, Sox2, Klf4, c-Myc) can reprogram cells to a younger state. Partial reprogramming — activating Yamanaka factors briefly and then turning them off — rejuvenates cells without causing them to lose their identity. In mouse studies, partial reprogramming restored vision in old mice and extended lifespan.
Rapamycin (sirolimus) is an FDA-approved immunosuppressant discovered in Easter Island soil bacteria in 1972. It inhibits mTOR (mechanistic target of rapamycin) — a master regulator of cell growth and metabolism. In every model organism studied (yeast, worms, flies, mice), mTOR inhibition extends lifespan by 20–40%. Rapamycin is the most reproducible longevity intervention in biology. Multiple clinical trials in healthy aging adults are now underway. The Interventions Testing Program (ITP) at the NIA gave rapamycin to middle-aged mice and saw a 23% lifespan extension — even starting at the equivalent of 60 human years.
The investor challenge: rapamycin is generic. No biotech captures the full value. Companies pursuing rapamycin analogs (rapalogs) with improved safety profiles — like Navitor Pharmaceuticals (private) or Ora Biomedical — represent the investment angle on this pathway.
The GLP-1 receptor agonists (semaglutide/Wegovy, tirzepatide/Mounjaro) are showing signals in cardiovascular, kidney, and — emerging — cognitive protection that go well beyond their weight loss effects. Trials in Alzheimer's disease, Parkinson's, ALS, and sleep apnea are underway. If GLP-1 drugs prove to extend healthspan by reducing the incidence of multiple age-related diseases, Eli Lilly (LLY) and Novo Nordisk (NVO) become de facto longevity stocks with enormous pipelines and profitable revenue today — a very different risk profile from pure-play longevity biotechs.
The public longevity market is frustrating for investors: most leading companies (Altos Labs, Calico, Oisin Biotech, Retro Biosciences) are private. The pure-play public options are small and early-stage.
Geron's imetelstat (Rytelo) received FDA approval in June 2024 for myelodysplastic syndromes (MDS) — a blood cancer. Geron is not a pure longevity play in the popular sense; it targets cancer with a telomere-targeting mechanism. But it is the only public company with an approved telomere-related therapy. Small-cap (~$1.5B) with a recently approved product entering commercial ramp.
Unity is the public senolytic pure-play. After setbacks in knee osteoarthritis (UBX0101 Phase 2 failed 2020), the company pivoted to ophthalmology. UBX1325 targets senescent cells in the retina — smaller addressable market but cleaner biology. Nano-cap (<$100M market cap); high clinical risk; thin cash runway. Pure venture-type bet on senolytic science.
Not purely longevity-focused, but Recursion's AI + biology platform is being used for aging-related diseases. Backed by Nvidia (which made a strategic investment). Partnerships with Roche and Bayer. Uses high-throughput cellular imaging and ML to map disease biology and identify drug candidates orders of magnitude faster than traditional approaches.
For investors who want sector exposure without picking individual stocks, three ETFs are most relevant. Performance context matters: XBI's 5-year return of +45% vs the S&P 500's +110% shows how badly small-cap biotech has underperformed the broader market since 2021 — sector selection risk is real.
The most concentrated gene-editing and genomics ETF. Run by Cathie Wood/ARK Invest. Active management means heavy concentration in high-conviction positions — ARKG can own 5–8% in individual names. High tracking error vs passive biotech. Suitable for investors who want active bet on genomics without individual stock selection.
The standard small/mid-cap biotech ETF. Equal-weighted (not market-cap weighted), which gives disproportionate exposure to small companies — including CRISPR and longevity names. 5-year performance: +45% (vs S&P +110%). Cheaper than ARKG and more diversified, but still volatile. The right vehicle for broad biotech exposure beyond genomics.
Market-cap weighted, so dominated by large-cap biopharma. Lower CRISPR/longevity exposure than ARKG or XBI, but lower volatility. More defensive biotech play. Vertex (VRTX) is a top-5 holding and a direct Casgevy commercial partner — one indirect longevity/CRISPR play embedded in a large-cap ETF.
Biotech's defining feature is binary risk: a Phase 3 trial failure can send a stock down 60–80% in a single day, while approval can 3–5x a stock. Every name in this guide — NTLA, CRSP, BEAM, EDIT, GERN, UBIX — has at least one pivotal trial result expected in the next 24 months. The base rate: ~80% of drugs that enter Phase 1 never get approved. Even Phase 3 has a ~50% failure rate across all indications.
The foundational CRISPR patents are contested between two groups: Jennifer Doudna's team at UC Berkeley (who first demonstrated CRISPR-Cas9 editing in a test tube) and Feng Zhang's team at the Broad Institute (who demonstrated it works in human cells). The Broad currently holds the key eukaryotic CRISPR patents in the US — relevant to all human therapeutic applications. The dispute has been ongoing for a decade with multiple USPTO and court rulings. The risk: licensing cost uncertainty and potential royalty obligations that change companies' economics. Beam Therapeutics, which is founded by Broad-affiliated scientists and holds Broad licenses, is better positioned here than CRISPR Therapeutics, which is UC Berkeley-aligned.
Ex vivo gene therapies require patient-specific manufacturing — each batch is made for a single patient. This is enormously complex, costly, and difficult to scale. Casgevy's slow commercial ramp (~60 patients in 1.5 years despite 100,000 eligible) reflects this bottleneck. Any delay in manufacturing, quality control failure, or supply chain disruption can significantly harm commercial timelines.
CRISPR can occasionally edit the wrong part of the genome — "off-target" cuts. While guide RNA design has become highly precise, and no approved CRISPR therapy has shown clinical harm from off-target effects, the risk is not zero. Regulatory agencies require extensive off-target characterization. Base editing (Beam) was specifically designed to address this by avoiding double-strand breaks. Any unexpected safety signal in any CRISPR trial could trigger regulatory scrutiny of the entire field.
NTLA ($900M cash), BEAM ($1.1B), and CRSP ($1.8B) have meaningful runways. EDIT at ~$350M and ~2-year runway is the most at risk. Any company that needs to raise capital in a difficult biotech environment will dilute existing shareholders. Watch quarterly cash burn vs runway on every earnings call.
CRISPR and longevity biotech should be treated like venture capital positions within a public portfolio: high potential upside, real probability of total loss for individual names, and 5–10 year time horizons. The framework:
Own 3–5 names across the CRISPR landscape rather than concentrating in one. The companies are genuinely differentiated — CRSP has an approved product, NTLA has the in vivo platform lead, BEAM has the precision advantage, EDIT has IP leverage. If the CRISPR space is successful, owning all four captures the winner regardless of which specific platform dominates. If one company has a major clinical failure, the others likely continue independently.
CRISPR gene editing has crossed the most important threshold: a therapy has been approved and is treating real patients. Casgevy is working. The question is no longer whether CRISPR can be a medicine — it demonstrably can. The question is which companies successfully navigate clinical trials, build commercial infrastructure, and survive long enough to capture the value.
The two-track framework matters for portfolio construction. CRISPR companies (CRSP, NTLA, BEAM) have identifiable near-term catalysts, binary trial outcomes, and paths to FDA approval this decade. CRSP is the most de-risked with an approved product; NTLA has the most transformative platform if in vivo delivery scales; BEAM has the most precise technology with the most capital to pursue it. EDIT is the highest-risk fourth option.
Longevity biology is a longer, more speculative bet. The science is genuinely advancing — rapamycin, senolytics, and epigenetic reprogramming have real animal data — but mouse-to-human translation in aging has a poor track record. The best longevity investments for most investors are the large-cap adjacencies: LLY and NVO if GLP-1 proves to extend healthspan, Alphabet if Calico produces a breakthrough, and a basket approach through ARKG for targeted genomics exposure.
Compare Intellia, CRISPR Therapeutics, and other gene editing stocks side-by-side on our stock analysis tool.